SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
SK Hynix Shares Fall as Workers Reject Wage Deal 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Nvidia Options Price in $280 Billion Earnings Swing 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
California Seeks Paramount Divestitures in Warner Bros. Merger 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Add as a preferred source on Google
EMERYVILLE, Calif., May 02, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 2:50 p.m. EDT
- Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 1:40 p.m. PDT
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]
